As a result, GLP-1 coverage for medically accepted FDA-approved indications other than obesity is required while access to GLP-1s to treat obesity under Medicaid is currently limited
Common adverse effects of GLP-1 receptor agonists include: Gastrointestinal symptoms (nausea, vomiting, diarrhoea, constipation) Injection site reactions Headache Fatigue Dizziness Important safety considerations include: Risk of hypoglycaemia when used with insulin or sulfonylureas (dose reduction of these agents may be needed) Potential worsening of diabetic retinopathy with semaglutide in patients with pre-existing retinopathy Risk of dehydration and acute kidney injury from persistent vomiting or diarrhoea Pancreatitis, gallbladder disease, and potential thyroid C-cell tumours (observed in rodent studies, though human relevance remains uncertain) Patients should be counselled about persistent severe abdominal pain as a potential warning sign of pancreatitis requiring immediate medical attention
When she is not pursuing medicine, you can find her reading, exploring artistic passions, and spending time connecting with friends and family
Tirzepatides Tirzepatides are medications that mimic two natural hormones (GLP-1 and GIP) to help regulate blood sugar and appetite
However, recent clinical evidence has highlighted Ozempics remarkable effectiveness in promoting weight loss, even in patients without diabetes
Its convenience makes it a strong contender for patients seeking oral GLP-1 weight loss options
